Creation
Draft
Initial
Signpost/Archive
Idea Description
Supplementary Information
Detailed Submission Data
Innovation 'Elevator Pitch':
Peezy Midstream: proven urine collection device, reducing specimen contamination from national average 22.5% to 2.5%. Collects specimen into either 30ml Universal Container or the 10ml lab-friendly Primary Tube. Cost: 87p on the NHS Catalogue.
Overview of Innovation:
Peezy Midstream is a proven urine collection device which reduces contamination risk from a national average 22.5% to 1.5-2.5%.

The Peezy is key for the pre-analytical diagnostic phase because:
  • The clean collection of Urine is a key component of laboratory medicine, drug and substance testing.
  • Pre-analytical specimen integrity is just as critical to the result reported by the laboratory. Drug testing and clinical laboratories must ensure processes are in place to ensure specimen collection is clean and free of contamination.
  • Contaminates and mixed growth can lead to corrupted or rejected samples.
The Peezy is the only device that provides a clean-catch mid-stream urine, it voids the initial stream into the toilet, removing the need to start-stop-start, it significantly reduces asymptomatic bacteriuria, it is hygienic and has been designed for use in drug testing.

- ISO 15189 / Laboratory Standards
  • Using the Peezy improves ISO 15189 reporting and quality measurements

Adopting the Peezy as the standard model for all urine collection allows laboratories to measure the number of urine samples received in the laboratory uncontaminated and to compare this to the number of contaminated urine samples received as a % of all urine samples processed, a key quality measure of the pre-analytical phase.

Peezy Midstream addresses an overlooked area of diagnostic medicine, delivers accuracy, hygiene and dignity. For those who are elderly or otherwise unable to position the device themselves, help can be hygiencially given with the carer holding the tube in place by the tube. This can be done over the toilet, a commode or bedpan.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content2
Innovation 'Elevator Pitch':
65m urine specimens analysed annually in the UK breaks down to 250,000 every working day, of which 45,000 will be unreliable. This means 45,000 patients daily who will not be treated for urine-based infections. Peezy Midstream means they can.
Overview of Innovation:
Peezy Midstream can save the NHS £30m in reduced retesting of the most common diagnostic procedure.

It is a simple but innovative device that automatically captures clean-catch urine from men, women and children (from toddler age). It is especially valuable for the elderly and pregnant women for whom accurate urine screening is essential.

The average national mixed growth rate reaches from 0.38% to over 70%; the average is 18% - that's nearly 1 in 5 patients who will not receive accurate right-first-time treatment from their urine specimen.

Peezy Midstream reduces mixed growth rates to 1.5%, which means many more patients will be treated right-first-time, saving the NHS as a whole over £30m in direct retest costs and over £1bn indirectly through saving repeat staff and resource time.

Peezy Midstream captures urine specimens hygienically - it prevents spills and splashing, improving infection control in healthcare settings. It can be held by the tube if help needs to be given - the assistant does not risk becoming soiled either.

Dignity is implicit; easy Peezy is comfortable, quick and removes the need to start-stop-start when giving a midstream urine specimen.

There is no down-side to using Peezy Midstream. It saves lives, saves time and money and reduces unnecessary broad spectrum anitbiotic prescribing. Peezy is poised to make novel cancer urine tests more efficient too.

Each Peezy kit costs just 87p on the NHSSC; use ten for every retest. Available on the NHS Supply Chain and on the UK Drug Tariff - growing in popularity with midwives and care givers to the elderly.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Peezy Midstream delivers huge cost and efficiency savings plus clinical benefits:

(See attached WM mixed growth data and separate cost savings model)
  • Reduction of average West Midlands mixed growth rate of 17.5% to 1.5%
  • West Midlands direct savings of £307,798
  • West Midlands indirect savings of £12,339,337 (see attached WM cost savings model)
  • reduced urine specimen mixed growth from West Midlands average  to 1.5%
  • right-first-time urine analysis, diagnosis and treatment - don't see the same patient twice for the same problem
  • delivers specimen into 10ml tube that fits most automated laboratory urine analysers (no decanting in lab)
  • no soiling, dry tube, clean toilets: more hygienic for healthcare professionals
  • targeted prescribing, reducing need for broad spectrum antibiotics
  • improved infection control: no spills or splashing of urine
  • works equally for men, women and children (from toddler age)
  • excellent for pregnant women where antenatal screening must be super-accurate; they don't have to see the funnel is in place - they can feel it
  • antenatal screening accuracy for maternal diabetes, pre-eclampsia
  • excellent for the elderly prone to UTI, which can affect both wellbeing and behaviour
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • West Midland Patient Savings of £90 (please see attached WM cost savings model, Patient Savings tab)
  • Accurate urine specimens mean prompt, accurate diagnoses
  • Patients will no longer need to visit their GP more than once for urine-related illnesses
  • They will receive the correct, targeted antibiotic, helping the fight against anitmicrobial resistance, encouraged by over prescribing of broad spectrums
Current and planned activity: 
  • Peezy Midstream is on the NHS Supply Chain at 87p (Peezy, tube, genital wipe)
  • It is approved by NHS Prescription Services and on the Drug Tariff for prescribing
  • Quality Improvement Audit at Barts (London) shows reduction in mixed growth from 17.5% to 1.5%
  • Quantative clinical study results pending from Stanford Medical School
  • Peezy currently part of MS Rapid Diagnostics Pilot, London
  • Prescribing growing amongst antenatal population
  • In use within some NHS departments: urology, outpatients, pre-admission, antenatal, A&E, Ambulance Services
What is the intellectual property status of your innovation?:
Patent and trademark granted:
  • UK
  • USA
  • Europe
  • China
  • Australisa
  • Asia
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Easy; Peezy is available through the NHS Supply Chain
Forte Medical is happy to attend your location and brief staff on usage and instructions if necessary
Measures:
Reduced mixed growth
Reduced retesting
Reduced repeat appointments
Cost and efficiency savings
Adoption target:
6 months
Read more
Hide details
Innovation 'Elevator Pitch':
Peezy Midstream delivers right first time urine analysis, diagnosis & treatment by reducing mixed growth from national average 18% to 1.5%. Reduces costly retesting, repeat appointments and unnecessary antibiotic prescribing. Saves time and money.
Overview of Innovation:
Peezy Midstream is new technology that guarantees midstream urine for essential tests and routine screening. It reduces the national average mixed growth rate from 18% to 1.5%; Peezy meets all the criteria for the Department of Health's Getting It Right First Time Programme.

Peezy is on the NHS Supply Chain and the National Drug Tariff, which means it can be prescribed for antenatal and elderly use, where truly accurate results are essential for mental and physical wellbeing of patients.

Urine analysis is used for myriad routine and exceptional diagnoses from chronic urinary tract infection to bladder cancer; prompt and efficient treatment brings benefits to clinicians and patients alike saving valuable time and money.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details

Created by

Share and Follow